We are live on
!
Find out more
LCM
Lynx1 Capital Management Portfolio holdings
AUM
$633M
1-Year Est. Return
173.22%
This Fund
S&P 500
This Quarter
Est. Return
+71.02%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$254M
AUM Growth
+$103M
(+68%)
Cap. Flow
+$21.9M
Cap. Flow
% of AUM
8.59%
Top 10 Holdings %
Top 10 Hldgs %
97.12%
Holding
18
New
–
Increased
9
Reduced
1
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$19.6M |
| 2 |
Stoke Therapeutics
STOK
|
+$5.33M |
| 3 |
GH Research
GHRS
|
+$5.19M |
| 4 |
C4 Therapeutics
CCCC
|
+$4.82M |
| 5 |
AUTL
Autolus Therapeutics
AUTL
|
+$1.89M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
+$14.8M |
| 2 |
MRUS
Merus
MRUS
|
+$350K |
| 3 |
Zura Bio
ZURA
|
+$65.5K |
| 4 |
DBVT
DBV Technologies
DBVT
|
+$24.8K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALPN
1
DELISTED
Alpine Immune Sciences Inc
ALPN
| $72.7M | 28.58% |
3,813,926
+1,409,312
| +59% | +$19.6M |
|
2
Cabaletta Bio
CABA
$439M
| $47.9M | 18.84% |
2,110,401
+4,401
| +0.2% | +$74K |
|
|
MRUS
3
DELISTED
Merus
MRUS
| $31.2M | 12.28% |
1,135,225
-15,000
| -1% | -$350K |
|
4
TScan Therapeutics
TCRX
$51.9M
| $30.5M | 11.98% |
5,224,600
| – | – |
|
|
5
C4 Therapeutics
CCCC
$376M
| $17.7M | 6.96% |
3,134,396
+2,115,166
| +208% | +$4.82M |
|
|
6
Stoke Therapeutics
STOK
$1.82B
| $15.6M | 6.12% |
2,956,918
+1,246,764
| +73% | +$5.33M |
|
|
AUTL
7
Autolus Therapeutics
AUTL
$386M
| $12M | 4.71% |
1,858,409
+495,384
| +36% | +$1.89M |
|
|
8
GH Research
GHRS
$1.87B
| $10.7M | 4.19% |
1,838,617
+735,439
| +67% | +$5.19M |
|
|
KNTE
9
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $4.73M | 1.86% |
1,997,006
| – | – |
|
|
SLN
10
Silence Therapeutics
SLN
$521M
| $4.1M | 1.61% |
235,787
| – | – |
|
|
THRX
11
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $2.84M | 1.12% |
702,415
| – | – |
|
|
PVLA
12
Palvella Therapeutics
PVLA
$1.98B
| $1.78M | 0.7% |
122,198
| – | – |
|
|
NEUP
13
Neuphoria Therapeutics
NEUP
$19.7M
| $1.22M | 0.48% |
68,692
+733
| +1% | +$20.9K |
|
14
Nektar Therapeutics
NKTR
$2.39B
| $1.09M | 0.43% |
128,613
+10,825
| +9% | +$82K |
|
15
Passage Bio
PASG
$15.9M
| $383K | 0.15% |
18,958
+9,452
| +99% | +$130K |
|
|
DBVT
16
DBV Technologies
DBVT
$807M
| – | – |
-1,827
| Closed | -$24.8K |
|
|
17
Zura Bio
ZURA
$497M
| – | – |
-9,917
| Closed | -$65.5K |
|
|
CBAY
18
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-994,161
| Closed | -$14.8M |
|
Similar funds
SWM
RFA
WA
AMM
EIM
SWP
ACM
BI
Lynx1 Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Lynx1 Capital Management held 18 positions worth $254M, up 68% from $151M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Lynx1 Capital Management deployed $21.9M of net new capital in Q4 2023, adding to 9 existing holdings.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Merus, an estimated $350K trimmed.
- Lynx1 Capital Management added most to Alpine Immune Sciences Inc in Q4 2023, an estimated $19.6M increase.
- Lynx1 Capital Management's biggest Q4 2023 reduction was Merus, cutting an estimated $350K.
- Lynx1 Capital Management fully exited Cymabay Therapeutics in Q4 2023, selling an estimated $14.8M.
- Lynx1 Capital Management's ten largest holdings make up 97% of its $254M portfolio in Q4 2023.
- Lynx1 Capital Management opened 0 new positions and closed 3 in Q4 2023.
- Lynx1 Capital Management's portfolio value rose 68% quarter-over-quarter to $254M.
Based on Lynx1 Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.